SC
TCRT icon

Schubert & Co’s Alaunos Therapeutics TCRT Stock Holding History

Schubert & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$145 – 1345
2023
Q1 		$145 Hold
2
– – ﹤0.01% 1575
2022
Q4 		$149 Hold
2
– – ﹤0.01% 1542
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1575
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1591
2022
Q1 		$0 Buy
2
+1
+100% +$128 ﹤0.01% 1327
2021
Q4 		$0 Buy
+1
New +$220 ﹤0.01% 1278

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schubert & Co's TCRT Position: Q2 2023 in Review

Schubert & Co sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 2 shares — an estimated $145 sold.

Schubert & Co first reported a position in TCRT in Q4 2021 and held it in 6 quarters. The position peaked at $149 in Q4 2022. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Schubert & Co reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 2 Alaunos Therapeutics shares in Q2 2023, an estimated $145.
  • Schubert & Co first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Alaunos Therapeutics position peaked at $149 in Q4 2022.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.